【24h】

Use of aripiprazole in tardive dyskinesia: an open label study of six cases.

机译:阿立哌唑在迟发性运动障碍中的使用:一项开放性研究,涉及6例病例。

获取原文
获取原文并翻译 | 示例
           

摘要

Aripiprazole, a partial dopamine agonist has been reported to help reduce symptoms of tardive dyskinesia (TD). In a prospective, open label study of a series of cases, we examined the effectiveness of aripiprazole in reducing TD symptoms. Six clinically stable patients with schizophrenia or Schizoaffective disorder and a moderate to severe TD participated in this study. They were systematically cross-titrated from their current medication to aripiprazole and maintained for 16 weeks. The mean extra pyramidal symptom score measured by Abnormal Involuntary Movement Scale (AIMS) improved from a baseline score of 15.8 to final score of 5 (paired t-test; P=0.0009). The severity of psychiatric symptoms remained unchanged. This study supports our hypothesis that clinically stable patients with moderate tardive dyskinesia who are under treatment with other first- or second-generation antipsychotics may benefit from switching to aripiprazole with a reduction of TD symptoms but with out any significant benefit in psychiatric symptoms. The results need to be viewed with caution and not considered as indicative of a viable treatment option for TD as this is an open label study, and a small sample size.
机译:据报道,阿立哌唑是一种多巴胺的部分激动剂,有助于减轻迟发性运动障碍(TD)的症状。在一系列病例的前瞻性,开放标签研究中,我们研究了阿立哌唑在减轻TD症状方面的有效性。六名临床稳定的精神分裂症或精神分裂症患者和中度至重度TD患者参加了这项研究。他们从目前的药物系统地交叉滴定到阿立哌唑,并维持16周。通过异常非自愿运动量表(AIMS)测量的平均锥体束外症状评分从基线评分15.8改善为最终评分5(配对t检验; P = 0.0009)。精神症状的严重程度保持不变。这项研究支持我们的假设,即正在接受其他第一代或第二代抗精神病药治疗的中度迟发性运动障碍的临床稳定患者可能会受益于改用阿立哌唑,减少TD症状,但对精神症状没有任何明显益处。需要谨慎对待结果,而不应将其视为TD可行治疗方案的指标,因为这是一项开放标签研究,并且样本量较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号